Briefly, ANA titer was dichotomized to 1 1:80 and 1:160 groups due to limited reporting of titers in some of the historical data

Briefly, ANA titer was dichotomized to 1 1:80 and 1:160 groups due to limited reporting of titers in some of the historical data. disease-related symptoms, and platelet count. In the logistic regression model, AUC was 0.83 (95% CI 0.79-0.86) in the training collection and 0.75 (95% CI 0.68-0.81) in the validation collection. == Summary == We developed and validated a risk model that predicts risk for developing systemic autoimmune diseases and can become deployed easily within the EHR. The model can risk stratify positive ANA individuals to ensure high-risk individuals receive urgent rheumatology referrals while reassuring low-risk individuals and reducing unneeded referrals. Keywords:antinuclear antibodies, electronic health record, risk model, autoimmune disease, rheumatology == 1. Intro == Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across multiple specialties (13). Currently, no clinically available or validated tools exist to help Myricitrin (Myricitrine) clinicians determine the significance of a positive ANA. While a positive ANA serves as a diagnostic criterion for multiple autoimmune diseases, the test only only has a 11% positive predictive value for systemic autoimmune disease (4). In US studies, rates of positive ANAs in the general human population without autoimmune disease range from 14% to 27% (5,6). Frequent, inappropriate purchasing of ANA screening has been recognized as a clinical problem from the American Table of Internal Medicine and the American College of Rheumatology in their Choosing Sensibly campaign. Specifically, it is recommended to not order an ANA test unless specific symptoms for an autoimmune disease are present (7,8). Up to 22% of all rheumatology referrals are for any positive ANA (1,9). Only 11-20% of individuals having a positive ANA have an autoimmune disease diagnosed at referral (4,1013). Frequent ANA referrals in the establishing of an international shortage of pediatric and adult rheumatologists (1416) contribute to inefficient use of limited resources and lengthen wait instances for rheumatology discussion (1,9,12). Triage systems and electronic consultations have attempted to tackle the problem of frequent ANA referrals with limited success (12,1720). Risk models have been developed for systemic lupus erythematosus Myricitrin (Myricitrine) (SLE) (21,22) but not for multiple systemic autoimmune diseases associated with a positive ANA. We targeted to develop and validate a powerful risk model for use in the rheumatology medical center that uses readily available data in the electronic health record (EHR) to identify which individuals with a positive ANA are at high and low risk for developing systemic autoimmune disease. == 2. Methods == == 2.1. Data source and patient selection == Myricitrin (Myricitrine) After receiving approval from your Vanderbilt University Medical Center (VUMC) IRB (#210189), we used the Synthetic Derivative, a de-identified version of the EHR that contains billing code and medical data on over 3.6 million individuals spanning across three decades (23). Records from outside VUMC are not available. We put together all individuals within the Synthetic Derivative who experienced a positive ANA, defined as a titer 1:80 (Supplementary Number 1). For ANA screening, the Hep-2 immunofluorescence assay was used for the entire study period (Appendix). We selected a random sample of 2,000 individuals with a positive ANA to perform chart review to assess for the model end result and collect covariates. Model end result was defined as developing a systemic autoimmune disease diagnosed by a rheumatologist, as EHR notes often lack systematic paperwork of disease criteria (24). We performed chart review for development of systemic autoimmune disease from time of 1st positive ANA up to ten years later or individuals last EHR connection. We allowed up to ten years, as individuals with autoimmune diseases can face significant diagnostic delays (25). Systemic autoimmune diseases are outlined inSupplementary Table 1. In addition Mouse monoclonal to PRKDC to diseases classically associated with a positive ANA (i.e., SLE, Sjogrens, systemic sclerosis, combined connective cells disease, and idiopathic inflammatory myopathies), we included additional systemic autoimmune diseases such as rheumatoid arthritis (RA) and seronegative conditions (we.e., psoriatic arthritis, ankylosing spondylitis). Since the risk model will be used for triage to the rheumatology medical center, we aimed to include individuals with systemic autoimmune diseases who would become followed in that setting. While the ANA is not part of medical criteria for.